What's in Fresenius Kabi's pipeline?

Fresenius Kabi has 21 drugs in our index: 21 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Fresenius Kabi's portfolio?

Top competitors by shared drug class: , Sanofi, Assistance Publique - Hôpitaux de Paris, Rigshospitalet, Denmark, Fresenius Kabi.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fresenius-kabi.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Fresenius Kabi — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fresenius Kabi (FRE.DE) pipeline: 21 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

FRE.DE (Frankfurt Stock Exchange) 21 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Perikabiven In Plastic Container	SODIUM GLYCEROPHOSPHATE	marketed			Metabolic	2014-01-01
Bloxiverz	NEOSTIGMINE	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	Neuroscience	2013-01-01
Tygacil	TIGECYCLINE	marketed	Tetracycline-class Antibacterial [EPC]	30S ribosomal subunit	Infectious Disease	2005-01-01
Unithroid	LEVOTHYROXINE SODIUM	marketed	l-Thyroxine	Thyroid hormone receptor beta	Oncology	2000-01-01
Naropin	ROPIVACAINE	marketed	Amide Local Anesthetic	Sodium channel protein type 5 subunit alpha	Pain	1996-01-01
Zemuron	ROCURONIUM	marketed	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	Neuroscience	1994-01-01
Diprivan	Propofol	marketed	General anesthetic	GABA A receptors	Neuroscience	1989-01-01
Dilaudid-Hp	HYDROMORPHONE	marketed	Opioid Agonist	mu-opioid receptor	Neuroscience	1984-01-01
Pentam	PENTAMIDINE	marketed	Antiprotozoal	Muscarinic acetylcholine receptor M4	Metabolic	1984-01-01
Dilaudid-Hp	Hydromorphone Hydrochloride	marketed	Opioid agonist	Mu-opioid receptor	Neuroscience	1984-01-01
Oxytocin 5 Usp Units In Dextrose 5%	OXYTOCIN	marketed	Adrenocorticotropic Hormone [EPC]	Oxytocin receptor	Neuroscience	1980-01-01
Nesacaine-Mpf	CHLOROPROCAINE	marketed	Ester Local Anesthetic	Sodium channel protein type 10 subunit alpha	Pain	1955-01-01

Therapeutic area mix

Neuroscience · 7
Metabolic · 2
Pain · 2
Infectious Disease · 1
Cardiovascular · 1
Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2026-07-24 — Lignospan Forte · 8759401 · Formulation · US
2028-10-24 — Tygacil · 8975242 · US
2029-02-05 — Tygacil · 7879828 · US
2029-10-22 — Lignospan Forte · 8540665 · Method of Use · US
2030-10-08 — Tygacil · 8372995 · US
2033-04-07 — Tygacil · 9855335 · US
2035-04-27 — Lignospan Forte · 9358338 · Method of Use · US
2035-09-28 — Lignospan Forte · 9370622 · Method of Use · US

Competitive overlap (companies sharing drug classes)

· 6 shared drug classes
Sanofi · 3 shared drug classes
Assistance Publique - Hôpitaux de Paris · 3 shared drug classes
Rigshospitalet, Denmark · 2 shared drug classes
Fresenius Kabi · 2 shared drug classes
Pfizer · 2 shared drug classes
Anemia Working Group Romania · 1 shared drug class
Amphastar Pharms Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fresenius Kabi:

Cite this brief

Drug Landscape (2026). Fresenius Kabi — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fresenius-kabi. Accessed 2026-06-10.